Current stock page

Financial Data

RVMD Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

RVMDRevolution Medicines, Inc.

Healthcare / Biotechnology

Low Priority

In Line With Peers

NeutralEdge 5/10
$172.29−$4.06 (−2.30%)

Latest quote

  • Momentum
    73
  • Value
    39
  • Quality
    43
  • Risk resilience
    59
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$197.56M$0$0$0$0$0$0$0
Gross Profit$197.23M$0-$4.54M-$4.7M$0$0$0$0
Operating Income-$373.15M-$505.13M-$445.22M-$361.63M-$315.27M-$264.71M-$240.76M-$216.31M
Net Income-$407.46M-$644.37M-$453.82M-$364.89M-$305.21M-$247.79M-$213.42M-$194.57M
EPS-$1.9-$3.06-$2.29-$1.9-$1.61-$1.31-$1.13-$1.13
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$415.65M-$387.32M-$354.17M-$274.24M-$207.31M-$221.76M-$194.44M-$138.29M
Capital Expenditure-$3.7M-$2.29M-$1.54M-$1.93M-$3.35M-$7.45M-$3.27M-$1.22M
Free Cash Flow-$419.35M-$389.61M-$355.7M-$276.16M-$210.66M-$229.21M-$197.7M-$139.51M
Net Cash Provided By Operating Activities-$415.65M-$387.32M-$354.17M-$274.24M-$207.31M-$221.76M-$194.44M-$138.29M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$4.3B$4.32B$2.25B$2.35B$2.25B$2.43B$2.37B$2.56B
Total Debt$639.1M$641.93M$437.27M$158.7M$158.46M$132.79M$134.34M$135.84M
Cash And Cash Equivalents$615.91M$815.44M$440.94M$383.75M$217.44M$402.44M$333.55M$543.06M
Total Liabilities$1.9B$1.72B$753.82M$723.21M$655.02M$564.2M$287.2M$293.1M
Total Stockholders Equity$2.4B$2.61B$1.5B$1.63B$1.6B$1.87B$2.08B$2.27B
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio15.915.9719.9512.037.033.73.413
P/S ratio187.45———————
Debt To Equity0.270.250.290.10.10.070.060.06
Free Cash Flow Yield-3.77%-3.82%-3.58%-4.66%-6.92%-10.15%-8.49%-8.36%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio15.915.9719.9512.037.033.73.413
P/S ratio187.45———————
Return On Equity-77.89%-67.85%-91.45%-69.35%-60.18%-43.53%-33.56%-26.49%
Debt To Equity0.270.250.290.10.10.070.060.06

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-18.83x
Pb15.42x
EPS Growth Yoy-18.01%
Gross Margin95.16%
Operating Margin-852.98%
ROE-91.93%
ROIC-43.86%
Debt To Equity0.27
FCF Yield-3.87%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$172.29
Volume2.65M
RSI (14)39.68
MACD-3.56
MACD signal-2.23
MACD histogram-1.32
ADX (14)17.62
SMA (50)$194.46
SMA (200)$159.88
ATR (14)$10.07
Historical volatility (annualized)71.01%
Volume (20-day average)2.37M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score59/100
Beta1.3
Annual volatility68.69%
Max Drawdown-24.95%
Sharpe Ratio1.69
VaR (95%, 1-day)-3.97%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

RVMD Financial Data FAQ

What is Revolution Medicines, Inc.'s revenue?

Revolution Medicines, Inc.'s revenue is one of the core financial data points for RVMD. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Revolution Medicines, Inc.'s revenue growing?

Revenue growth shows whether Revolution Medicines, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is RVMD's EPS?

RVMD's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Revolution Medicines, Inc.'s net income?

Revolution Medicines, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Revolution Medicines, Inc. generate?

Free cash flow shows how much cash Revolution Medicines, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Revolution Medicines, Inc. have?

Cash and debt help frame RVMD's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.